Abstract

As early detection is crucial for improvement of cancer prognosis, we searched for biomarkers in plasma from individuals who later developed squamous cell carcinoma of the oral tongue (SCCOT) as well as in patients with an already established SCCOT. Levels of 261 proteins related to inflammation and/or tumor processes were measured using the proximity extension assay (PEA) in 179 plasma samples (42 collected before diagnosis of SCCOT with 81 matched controls; 28 collected at diagnosis of SCCOT with 28 matched controls). Statistical modeling tools principal component analysis (PCA) and orthogonal partial least square - discriminant analysis (OPLS-DA) were applied to provide insights into separations between groups. PCA models failed to achieve group separation of SCCOT patients from controls based on protein levels in samples taken prior to diagnosis or at the time of diagnosis. For pre-diagnostic samples and their controls, no significant OPLS-DA model was identified. Potentials for separating pre-diagnostic samples collected up to five years before diagnosis (n = 15) from matched controls (n = 28) were seen in four proteins. For diagnostic samples and controls, the OPLS-DA model indicated that 21 proteins were important for group separation. TNF receptor associated factor 2 (TRAF2), decreased in pre-diagnostic plasma (< 5 years) but increased at diagnosis, was the only protein showing altered levels before and at diagnosis of SCCOT (p-value < 0.05). Taken together, changes in plasma protein profiles at diagnosis were evident, but not reliably detectable in pre-diagnostic samples taken before clinical signs of tumor development. Variation in protein levels during cancer development poses a challenge for the identification of biomarkers that could predict SCCOT development.

Highlights

  • Proteins found in blood plasma can be informative of health status and disease risk [1]

  • In our recent study that focused on interleukin 1 receptor antagonist (IL-1Ra), a commonly suggested cancer biomarker, we found that IL-1Ra levels in pre-diagnostic samples has low potential as a predictive biomarker for SCCHN [11]

  • Three different multiplex panels consisting of 92 different proteins each were used for analysis of plasma taken between six months up to 22 years before Squamous cell carcinoma of the oral tongue (SCCOT) diagnosis, plasma collected at diagnosis from patients with SCCOT and from matched controls without any history of cancer

Read more

Summary

Introduction

Proteins found in blood plasma can be informative of health status and disease risk [1]. A number of FDA (US Food and Drug Administration)-approved plasma protein biomarkers for Plasma Proteins and SCCOT cancer are currently used in clinical practice, such as prostatespecific antigen (PSA) for prostate cancer, alpha-fetoprotein (AFP) for testicular cancer, cancer antigen 125 (CA-125) for ovarian cancer, CA 15-3 for breast cancer and CA 19-9 for pancreatic cancer [3, 4]. Despite their approved application, insufficient specificity for cancer diagnosis or management is well recognized [2, 3]. Cancer-specific changes that can be detected at an early phase of cancer development are of great value for increasing the chances of successful treatment and better prognosis [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call